ClinicalTrials.gg

Program

BNT162 Vaccine

Also written as “BNT162b2”, “BNT162b1” and “BNT162b2 Vaccine”.

Its studies are mostly in COVID-19 · Influenza, Human · Pneumococcal Infections, led by 3 companies.

Furthest: phase 4, since Oct 14, 202023 company-led studies, 3 open or runningNext primary completion: Apr 21, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTech202 open or runningphase 4since Oct 14, 2020Apr 27, 2020Apr 21, 2027phase 3 · NCT07798648
Pfizer20 open or runningphase 3since May 10, 2021May 10, 2021none ahead
PharmaJet11 open or runningphase 2since Apr 3, 2025Apr 3, 2025none ahead

Also a collaborator on its studies: Fosun Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Apr 27, 2020.

  1. May 5, 2021Phase 2 study in COVID-19BioNTech · NCT04895982 · 124 enrolled · United States, Brazil, Germany and more
  2. May 10, 2021Pfizer's first study: phase 3 study in Pneumococcal InfectionsNew to PfizerPfizer · NCT04887948 · 570 enrolled · United States
  3. Jun 9, 2021Phase 3 study in COVID-19BioNTech · NCT04955626 · 16,372 enrolled · United States, Brazil, Germany and more
  4. Jun 25, 2021Phase 2 study in COVID-19BioNTech · NCT04949490 · 137 enrolled · Germany
  5. Aug 5, 2021Phase 2 study in COVID-19BioNTech · NCT05004181 · 1,380 enrolled · United States, Germany, South Africa and more
  6. Mar 25, 2022Phase 3 study in COVID-19BioNTech · NCT05310084 · 1,134 enrolled · Australia, New Zealand
  7. Aug 10, 2023Phase 3 study in COVID-19BioNTech · NCT05997290 · 1,051 enrolled · United States
  8. Jan 30, 2024Phase 2 study in Influenza, HumanPfizer · NCT06237049 · 644 enrolled · United States
  9. Apr 3, 2025PharmaJet's first study: phase 2 study in Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy VolunteersNew to PharmaJetPharmaJet · NCT06919796 · 40 planned · United States
  10. Jul 7, 2025Phase 3 study in COVID-19BioNTech · NCT07069309 · 774 enrolled · United States
  11. Oct 28, 2025Phase 3 study in COVID-19BioNTech · NCT07222384 · 344 enrolled · United States, Puerto Rico
  12. Nov 27, 2025Phase 3 study in COVID-19BioNTech · NCT07300839 · 5,240 enrolled · United States
  13. Jul 23, 2026Phase 4 study in PneumoniaBioNTech · NCT07730450 · 200 planned · United States
  14. Aug 28, 2026Phase 3 study in PneumoniaBioNTech · NCT07798648 · 700 planned · United States

Ahead

  1. Apr 21, 2027Primary completion: phase 3 study in PneumoniaBioNTech · NCT07798648
  2. Aug 20, 2027Primary completion: phase 4 study in PneumoniaBioNTech · NCT07730450

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07798648Pneumonia · United States3RecruitingBioNTechApr 21, 2027700
NCT07730450Pneumonia · United States4RecruitingBioNTechAug 20, 2027200
NCT07300839COVID-19 · United States3CompletedBioNTechSep 22, 20265,240
NCT07222384COVID-19 · United States, Puerto Rico3CompletedBioNTechJul 24, 2026344
NCT07069309COVID-19 · United States3CompletedBioNTechMay 1, 2026774
NCT06919796Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers · United States2Not yet recruitingPharmaJetMay 1, 202640
NCT06237049Influenza, Human · United States2CompletedPfizerSep 13, 2024644
NCT05997290COVID-19 · United States3CompletedBioNTechMar 13, 20251,051
NCT05310084COVID-19 · Australia, New Zealand3CompletedBioNTechOct 5, 20221,134
NCT05004181COVID-19 · United States, Germany, South Africa and more2CompletedBioNTechAug 16, 20231,380
NCT04949490COVID-19 · Germany2CompletedBioNTechApr 14, 2022137
NCT04955626COVID-19 · United States, Brazil, Germany and more3CompletedBioNTechMay 25, 202316,372
NCT04887948Pneumococcal Infections · United States3CompletedPfizerDec 8, 2021570
NCT04895982COVID-19 · United States, Brazil, Germany and more2CompletedBioNTechJul 23, 2023124
NCT04816669COVID-19 · United States3CompletedBioNTechDec 1, 2021629
NCT04816643COVID-19 · United States, Brazil, Finland and more3CompletedBioNTechOct 4, 202311,837
NCT04754594COVID-19 · United States, Brazil, South Africa and more3CompletedBioNTechJul 15, 2022726
NCT04713553COVID-19 · United States3CompletedBioNTechJul 22, 20211,574
NCT04649021COVID-19 · China2CompletedBioNTechFeb 7, 2021960
NCT04588480COVID-19 · Japan4CompletedBioNTechNov 25, 2021160
NCT04523571COVID-19 · China1CompletedBioNTechSep 30, 2020144
NCT04380701Respiratory Tract Infections · Germany2CompletedBioNTechJun 30, 2021512
NCT04368728COVID-19 · United States, Argentina, Brazil and more3CompletedBioNTechFeb 10, 202346,969

How it is read

Names in the registry

  • “BNT162b2”, 16 entries
  • “BNT162b1”, 3 entries
  • “BNT162b2 Vaccine”, 2 entries
  • “BNT162b2 (Omi XBB.1.5)”, 2 entries
  • “BNT162b2 (2025/2026 formulation)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.